Canada’s pharmaceutical industry is a key contributor to the global pharma market. Here are the top Canadian pharma stocks of 2021.
Click here to read the latest top Canadian pharma stocks article.
The life science sector is one of Canada’s key industries, and as a sub-sector the pharmaceutical industry represents 41 percent of Canada’s life science gross domestic product.
“Canada’s commercially oriented research network takes innovation from lab to market; joint investment opportunities in research allow for R&D result optimization; and the responsive and efficient regulatory environment facilitates business operations,” according to Invest in Canada.
In fact, the organization notes that 5 percent of the world’s clinical trials take place in Canada, making the country one of the 10 top medical research nations in the world.
Overall, the Canadian pharma sector is the 10th largest in the world and accounts for 2 percent of the global market. With a population of roughly 38 million as of 2020, Canada’s pharmaceutical market share is profound, and the country is home to companies making moves.
Below the Investing News Network profiles the top Canadian pharma stocks on the TSX, TSXV and CSE in terms of year-to-date performance. The top Canadian pharma stocks list below was compiled using TradingView’s stock screener, with all numbers current as of December 20, 2021. Each pharma stock on the list had a market capitalization of between C$10 million and C$500 million at that time.
1. Devonian Health Group
Current share price: C$0.50; year-to-date gain: 284.62 percent
Late-stage pharmaceutical company Devonian Health Group (TSXV:GSD) develops novel therapeutics, including prescription botanical drugs and cosmeceuticals from plant materials and algae. The company’s pipeline of product candidates targets worldwide unmet medical needs, including the treatment of inflammatory autoimmune diseases such ulcerative colitis and atopic dermatitis.
In March 2021, Devonian received a notice of allowance from the US Patent and Trademark Office for its patent application covering the use of Thykamine in adult patients with mild to moderate atopic dermatitis. This top Canadian pharma stock hit a year-to-date high of C$0.70 on May 27.
2. InnoCan Pharma
Current share price: C$0.81; year-to-date gain: 141.79 percent
The company has a worldwide exclusive license agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug-delivery platform based on a unique controlled-release liposome that is administered by injection. InnoCan’s pipeline includes a dermal product that integrates CBD with other pharmaceutical ingredients, such as topical treatments for the relief of psoriasis symptoms, muscle pain and rheumatic pain. Shares of InnoCan hit a year-to-date high of C$1.27 on September 13.
3. Cipher Pharmaceuticals
Current share price: C$1.69; year-to-date gain: 81.72 percent
Third on this list of top Canadian pharma stocks is Cipher Pharmaceuticals (TSX:CPH), which has developed a diversified portfolio of commercial and early to late-stage products. Commercial products are marketed directly in Canada and indirectly through partners in the US and South America.
Cipher Pharmaceuticals reported a 30 percent increase in product revenue year-to-date as of Q3, driven by strong sales of its Epuris and Absorica products. Shares reached a year-to-date high of C$2.80 on October 22.
4. IntelGenx Technologies
Current share price: C$0.49; year-to-date gain: 71.93 percent
Drug-delivery technology company IntelGenx Technologies (TSX:IGX) develops and manufactures pharmaceutical films that address many therapeutic conditions. Its film technologies include VersaFilm, VetaFilm and transdermal VevaDerm. IntelGenx also provides comprehensive services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property and regulatory services. The company’s manufacturing facility offers full services such as lab-scale to pilot- and commercial-scale production.
This top Canadian pharma stock hit a 2021 year-to-date high of C$0.85 on May 4. On October 7, IntelGenx graduated from the TSXV to the TSX.
5. Miravo Healthcare
Current share price: C$1.45; year-to-date gain: 59.34 percent
Miravo Healthcare (TSX:MRV) has a portfolio of commercial products targeting several therapeutic areas, including pain, allergies, neurology and dermatology. The company operates a good manufacturing practices-certified manufacturing facility in Quebec, Canada. Miravo also has international operations in Dublin, Ireland.
This top Canadian pharma stock hit a year-to-date high of C$2.50 on January 8. In August, Miravo announced that Health Canada had issued a notice of compliance for the company’s supplement to new drug submission for the pediatric use of Blexten, a second-generation antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
- 5 Top Pharmaceutical ETFs | INN ›
- 5 Biggest Pharmaceutical Companies in 2022 | INN ›
- Investing in Pharmaceutical Companies | INN ›
- 5 Biggest Canadian Pharma Stocks | INN ›
- Why Consider Investing in Pharmaceutical Stocks? | INN ›